[go: up one dir, main page]

WO2024011116A3 - Potent and selective irreversible inhibitors of irak1 - Google Patents

Potent and selective irreversible inhibitors of irak1 Download PDF

Info

Publication number
WO2024011116A3
WO2024011116A3 PCT/US2023/069627 US2023069627W WO2024011116A3 WO 2024011116 A3 WO2024011116 A3 WO 2024011116A3 US 2023069627 W US2023069627 W US 2023069627W WO 2024011116 A3 WO2024011116 A3 WO 2024011116A3
Authority
WO
WIPO (PCT)
Prior art keywords
irreversible inhibitors
irak1
potent
selective irreversible
compounds
Prior art date
Application number
PCT/US2023/069627
Other languages
French (fr)
Other versions
WO2024011116A2 (en
Inventor
John M. Hatcher
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Priority to EP23836235.4A priority Critical patent/EP4551218A2/en
Publication of WO2024011116A2 publication Critical patent/WO2024011116A2/en
Publication of WO2024011116A3 publication Critical patent/WO2024011116A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The disclosure relates to compounds that act as irreversible inhibitors interleukin 1 (IL-1 ) receptor-associated kinases (IRAKs); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
PCT/US2023/069627 2022-07-07 2023-07-05 Potent and selective irreversible inhibitors of irak1 WO2024011116A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23836235.4A EP4551218A2 (en) 2022-07-07 2023-07-05 Potent and selective irreversible inhibitors of irak1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263367875P 2022-07-07 2022-07-07
US63/367,875 2022-07-07

Publications (2)

Publication Number Publication Date
WO2024011116A2 WO2024011116A2 (en) 2024-01-11
WO2024011116A3 true WO2024011116A3 (en) 2024-02-15

Family

ID=89454132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/069627 WO2024011116A2 (en) 2022-07-07 2023-07-05 Potent and selective irreversible inhibitors of irak1

Country Status (2)

Country Link
EP (1) EP4551218A2 (en)
WO (1) WO2024011116A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055941A2 (en) * 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US9216991B2 (en) * 2012-07-10 2015-12-22 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
US9982000B2 (en) * 2015-04-22 2018-05-29 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
WO2021194982A1 (en) * 2020-03-23 2021-09-30 Dana-Farber Cancer Institute, Inc. Potent and selective irreversible inhibitors of irak1
US11542251B2 (en) * 2018-02-14 2023-01-03 Dana-Farber Cancer Institute, Inc. IRAK degraders and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055941A2 (en) * 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US9216991B2 (en) * 2012-07-10 2015-12-22 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
US9982000B2 (en) * 2015-04-22 2018-05-29 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
US11542251B2 (en) * 2018-02-14 2023-01-03 Dana-Farber Cancer Institute, Inc. IRAK degraders and uses thereof
WO2021194982A1 (en) * 2020-03-23 2021-09-30 Dana-Farber Cancer Institute, Inc. Potent and selective irreversible inhibitors of irak1

Also Published As

Publication number Publication date
EP4551218A2 (en) 2025-05-14
WO2024011116A2 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
PH12022552739A1 (en) Fused tricyclic kras inhibitors
CR20240059A (en) Tricyclic compounds as inhibitors of kras
EP4360713A3 (en) Quinazoline derivatives as antitumor agents
TW200510380A (en) Mitotic kinesin inhibitors
MX2022015739A (en) Allosteric egfr inhibitors and methods of use thereof.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PL1664026T3 (en) Mitotic kinesin inhibitors
WO2021074620A9 (en) [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors
NZ795564A (en) P38alpha mitogen-activated protein kinase inhibitors
JOP20220107A1 (en) Allosteric EGFR inhibitors and methods of their use
WO2020231739A3 (en) Compounds and methods for treating cancer
MX2023001296A (en) Compositions and methods for treating diseases and disorders.
CR20230180A (en) Interleukin-17 inhibitors
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
MX2023007150A (en) Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof.
PL1732926T3 (en) Mitotic kinesin inhibitors
WO2024011116A3 (en) Potent and selective irreversible inhibitors of irak1
WO2021161023A8 (en) Compounds useful in inhibiting ketohexokinase and methods of making and using the same
MX2023003516A (en) Cyclin-dependent kinase 7 (cdk7) non-covalent inhibitors.
WO2023205595A3 (en) Egfr inhibitors in cancer treatment
WO2023278603A3 (en) Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1), combinations and uses thereof
WO2023164175A3 (en) Protacs of malt1
ZA202107710B (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2022015493A (en) Imidazopyridazine compounds with activity as alk2 inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23836235

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2023836235

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023836235

Country of ref document: EP

Effective date: 20250207

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23836235

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2023836235

Country of ref document: EP